Pharma Focus Asia

CanariaBio Receives FDA Orphan Drug Designation for MAb-AR20.5 in Pancreatic Cancer

Tuesday, August 22, 2023

CanariaBio announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to their investigational drug product, MAb-AR20.5.

MAb-AR20.5 is a monoclonal antibody that specifically targets the MUC1 antigen, which is expressed on pancreatic cancer cells. This type of targeted therapy has the potential to be more effective and have fewer side effects compared to traditional treatments that affect healthy cells as well. 

The antibody has shown promise in early studies by inducing immune responses specific to the MUC1 antigen in patients with advanced pancreatic cancer. This is important because pancreatic cancer is known to be a challenging malignancy with limited treatment options available, and any new treatment strategies are welcomed advancements.

Overall, the development of MAb-AR20.5 as a potential treatment for pancreatic cancer is promising news, offering hope for patients and potentially improving the outlook for those affected by this aggressive disease. 

The orphan drug designation suggests that MAb-AR20.5 is being recognized for its potential to address an unmet medical need, particularly for patients with pancreatic cancer. 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products ConferenceĀ 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024